Akero Therapeutics is a biotechnology company that focuses on the development of innovative therapies for the treatment of chronic metabolic diseases, particularly non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The company is dedicated to advancing its pipeline of pharmaceutical candidates, utilizing its proprietary technology and a deep understanding of liver disease mechanisms to address unmet medical needs. By conducting rigorous clinical trials and research, Akero aims to deliver effective treatment options that can improve patient outcomes and contribute to the overall health of individuals affected by these conditions.